ASCO 2023: Digital Histopathology-Based Multimodal Artificial Intelligence Scores Predict Risk of Progression in a Randomized Phase III Trial in Patients with Nonmetastatic Castration-Resistant Prostate Cancer
Dr. Felix Feng presented on the use of digital histopathology-based multimodal artificial intelligence scores to predict risk [...]
Dr. McKay highlights the ArteraAI Prostate Test
In this interview, Dr. McKay discusses use of the ArteraAI test for prostate cancer risk stratification. Dr. McKay is a GU me [...]
Florida medical tech company launches novel AI test for prostate cancer therapy
ArteraAI’s ‘first-ever predictive test’ helps doctors choose personalized treatment for patients Fox News Article
Can Artificial Intelligence Help Diagnose Prostate Cancer?
AI may be a medical game-changer, with the power of machine learning advancing the efficacy of prostate cancer biopsies and m [...]
Andre Esteva of ArteraAI: 5 Things I Wish Someone Told Me Before I Became A CEO
Medium’s Doug Noll spoke with the CEO of ArteraAI, Andre Esteva, to discuss his path from Stanford University to founding fou [...]
ArteraAI and ACS form collaboration to use AI for designing personalized therapy
ArteraAI and the American Cancer Society formed a collaboration focused on the development of AI-driven cancer therapy person [...]
MMAI Model More Accurately Predicts Outcomes of High-Risk Prostate Cancer
Jessica Nye from Cancer Therapy Advisor discusses key findings, presented by Daniel Spratt, MD at ASCO GU 2023, demonstrating [...]
Multimodal AI Biomarker May Help Personalize Decision-Making in High-Risk Prostate Cancer
Mark Leiser from HemOnc Today discusses results from ArteraAI’s prognostic MMAI model that were presented by Daniel Spratt, M [...]
How AI can support the American Cancer Society’s IMPACT Initiative
Andre Esteva, Co-founder and CEO of ArteraAI, discusses how AI can support the ACS’ IMPACT initiative and other possibilities [...]